Open AccessPseudomonas aeruginosa Keratitis in Mice: Effects of Topical Bacteriophage KPP12 Administration
Author(s) -
Ken Fukuda,
Waka Ishida,
Jumpei Uchiyama,
Mohammad Rashel,
Shinichiro Kato,
Tatsuhito Morita,
Asako Muraoka,
Tamaki Sumi,
Shigenobu Matsuzaki,
Masanori Daibata,
Atsuki Fukushima
Publication year - 2012
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0047742
Subject(s) - keratitis , pseudomonas aeruginosa , microbiology and biotechnology , cornea , bacteriophage , phage therapy , corneal perforation , biology , virology , bacterial virus , antibiotics , bacteria , gene , escherichia coli , genetics , neuroscience
The therapeutic effects of bacteriophage (phage) KPP12 in Pseudomonas aeruginosa keratitis were investigated in mice. Morphological analysis showed that phage KPP12 is a member of the family Myoviridae , morphotype A1, and DNA sequence analysis revealed that phage KPP12 is similar to PB1-like viruses. Analysis of the phage KPP12 genome did not identify any genes related to drug resistance, pathogenicity or lysogenicity, and so phage KPP12 may be a good candidate for therapeutic. KPP12 showed a broad host range for P. aeruginosa strains isolated from clinical ophthalmic infections. Inoculation of the scarified cornea with P. aeruginosa caused severe keratitis and eventual corneal perforation. Subsequent single-dose administration of KPP12 eye-drops significantly improved disease outcome, and preserved the structural integrity and transparency of the infected cornea. KPP12 treatment resulted in the suppression of neutrophil infiltration and greatly enhanced bacterial clearance in the infected cornea. These results indicate that bacteriophage eye-drops may be a novel adjunctive or alternative therapeutic agent for the treatment of infectious keratitis secondary to antibiotic-resistant bacteria.